• Aucun résultat trouvé

[PDF] Top 20 Pharmacokinetic and toxicological considerations for the treatment of diabetes in patients with liver disease.

Has 10000 "Pharmacokinetic and toxicological considerations for the treatment of diabetes in patients with liver disease." found on our website. Below are the top 20 most common "Pharmacokinetic and toxicological considerations for the treatment of diabetes in patients with liver disease.".

Pharmacokinetic and toxicological considerations for the treatment of diabetes in patients with liver disease.

Pharmacokinetic and toxicological considerations for the treatment of diabetes in patients with liver disease.

... 4.1.Metformin The use of metformin has been limited in many diabetic patients considered as at risk of complications, especially lactic acidosis ...information and some current ... Voir le document complet

43

Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease.

Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease.

... - In case of contraindication to metformin (CL CR between 30-45 ml/min but at risk of destabilisation or CL CR < 30 ml/min), the physician may chose a DPP-4 inhibitor rather than a ... Voir le document complet

48

Pharmacokinetics in patients with chronic liver disease and hepatic safety of incretin-based therapies for the management of type 2 diabetes mellitus.

Pharmacokinetics in patients with chronic liver disease and hepatic safety of incretin-based therapies for the management of type 2 diabetes mellitus.

... subjects with normal liver function. According to the authors, because the half- life of liraglutide was not affected by HI, the differences in the overall exposure ... Voir le document complet

32

Dihydroceramides in Triglyceride-Enriched VLDL Are Associated with Nonalcoholic Fatty Liver Disease Severity in Type 2 Diabetes

Dihydroceramides in Triglyceride-Enriched VLDL Are Associated with Nonalcoholic Fatty Liver Disease Severity in Type 2 Diabetes

... Data and Code Availability The published article includes all datasets generated or analyzed during the ...MODELS AND SUBJECT DETAILS CERADIAB is a cross-sectional study, that included over a ... Voir le document complet

17

Practical Considerations for the Use of Subcutaneous Treatment in the Management of Dyslipidaemia

Practical Considerations for the Use of Subcutaneous Treatment in the Management of Dyslipidaemia

... MODE OF ADMINISTRATION There is increasing experience with the subcu- taneous (SC) route of administration from bio- logics in malignancies and inflammatory diseases [ 43 ... Voir le document complet

22

Pharmacokinetic evaluation of atorvastatin and sitagliptin in combination for the treatment of type 2 diabetes.

Pharmacokinetic evaluation of atorvastatin and sitagliptin in combination for the treatment of type 2 diabetes.

... Reductions in total and LDL cholesterol levels achieved with atorvastatin have been shown to translate into reductions in risk of cardiovascular morbidity and mortality in ... Voir le document complet

15

Dulaglutide (LY-2189265) for the treatment of type 2 diabetes.

Dulaglutide (LY-2189265) for the treatment of type 2 diabetes.

... pharmacokinetics of dulaglutide was well described by a 2-compartment model with first- order ...absorbed and t max at steady state ranged from 24 to 72 hours (median = 48 ...hours). The ... Voir le document complet

32

Prevalence of diabetes and the metabolic syndrome in a sample of patients with bipolar disorder.

Prevalence of diabetes and the metabolic syndrome in a sample of patients with bipolar disorder.

... all patients. Patients were initiated on an overnight fast and were monitored during the ...performed in the same laboratory. The presence of the metabolic ... Voir le document complet

8

Metabolic syndrome in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a post hoc analyses of the EMPA-REG OUTCOME trial

Metabolic syndrome in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a post hoc analyses of the EMPA-REG OUTCOME trial

... T2D and MetS, referred to as “with MetS” throughout the manuscript and ...undertaken in patients that were treated with at least one dose of study drug and ... Voir le document complet

10

Targeting the AMPK pathway for the treatment of Type 2 diabetes.

Targeting the AMPK pathway for the treatment of Type 2 diabetes.

... Benoît Viollet, Louise Lantier, Jocelyne Devin-Leclerc, Sophie Hébrard, Chloé Amouyal, et al... Tar- geting the AMPK pathway for the treatment of Type 2 diabetes...[r] ... Voir le document complet

3

Update on the treatment of pituitary adenomas: familial and genetic considerations.

Update on the treatment of pituitary adenomas: familial and genetic considerations.

... making the true risk of disease in muta- tion carriers ...that the penetrance of pituitary disease in AIP mutation-bearing FIPA kin- dreds may be relatively high, ... Voir le document complet

7

The veno-occlusive disease of the liver.

The veno-occlusive disease of the liver.

... cells and because of their ele- vated levels in patients before the onset of hepatic dysfunction associated with ...be the primary target of events leading ... Voir le document complet

8

Population pharmacokinetic analysis of free and bound aflibercept in patients with advanced solid tumors.

Population pharmacokinetic analysis of free and bound aflibercept in patients with advanced solid tumors.

... model, the MM parameters (V max , K m ) are related to TMDD model parameters: V max =k syn ...R and K m =K IB =k deg /k on , where V R is the volume of distribution of target and ... Voir le document complet

33

Cell and tissue engineering for liver disease

Cell and tissue engineering for liver disease

... rates with biomaterials, use of ectopic sites that do not harbor ongoing injurious stimuli, and the need for expansion of engrafted cells in response to regenerative cues ... Voir le document complet

50

Clinical and economic impact of diabetes mellitus on percutaneous and surgical treatment of multivessel coronary disease patients: insights from the Arterial Revascularization Therapy Study (ARTS) trial.

Clinical and economic impact of diabetes mellitus on percutaneous and surgical treatment of multivessel coronary disease patients: insights from the Arterial Revascularization Therapy Study (ARTS) trial.

... (CABG) and stenting for the treatment of diabetic patients with multivessel coronary disease enrolled in the Arterial Revascularization Therapy Study ... Voir le document complet

7

Usefulness of glycosylated haemoglobin (HbA1c) to screen for diabetes in patients with schizophrenia.

Usefulness of glycosylated haemoglobin (HbA1c) to screen for diabetes in patients with schizophrenia.

... Department of Diabetology, CHU de Sart Tilman, University Liège, Belgium Dear Editor, Metabolic abnormalities have consistently been identified as a part of schizophrenic ...illness. The interest ... Voir le document complet

2

DPP-4 inhibitors in the treatment of type 2 diabetes.

DPP-4 inhibitors in the treatment of type 2 diabetes.

... therapy and has shown clinically meaningful improvement of glycaemic control in type 2 ...weeks in drug-naïve patients or patients receiving oral antidiabetic agents (other than ... Voir le document complet

27

Burn after feeding. An old uncoupler of oxidative phosphorylation is redesigned for the treatment of nonalcoholic fatty liver disease.

Burn after feeding. An old uncoupler of oxidative phosphorylation is redesigned for the treatment of nonalcoholic fatty liver disease.

... effective for the treatment of NAFLD and associated metabolic disorders, additional investigations were carried out in rats fed a high-fat diet with ... Voir le document complet

15

International Day for the Evaluation of Abdominal Obesity (IDEA): a study of waist circumference, cardiovascular disease, and diabetes mellitus in 168,000 primary care patients in 63 countries.: Waist circumference, diabetes and CVD

International Day for the Evaluation of Abdominal Obesity (IDEA): a study of waist circumference, cardiovascular disease, and diabetes mellitus in 168,000 primary care patients in 63 countries.: Waist circumference, diabetes and CVD

... means, and standard deviations (SD). Regional frequencies of obesity (BMI ≥30 kg/m²), overweight (BMI 25- 30 kg/m²), CVD, and diabetes were standardized according to the age ... Voir le document complet

32

Treatment of type 2 diabetes.

Treatment of type 2 diabetes.

... risk and benefits As the prevalence of type 2 diabetes and the risk of severe side-effects of oral antidiabetic agents are markedly increased with aging, ... Voir le document complet

13

Show all 10000 documents...